336 related articles for article (PubMed ID: 2579440)
1. Third-line salvage chemotherapy in Hodgkin's disease.
Bonadonna G; Viviani S; Valagussa P; Bonfante V; Santoro A
Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
[TBL] [Abstract][Full Text] [Related]
2. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease.
Santoro A; Viviani S; Valagussa P; Bonfante V; Bonadonna G
Semin Oncol; 1986 Mar; 13(1 Suppl 1):23-6. PubMed ID: 2420012
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
[TBL] [Abstract][Full Text] [Related]
4. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients].
Cervantes F; Reverter JC; Bladé J; Montserrat E; Rozman C
Sangre (Barc); 1988 Jun; 33(3):184-7. PubMed ID: 2459787
[No Abstract] [Full Text] [Related]
7. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
Lopez M
Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
[No Abstract] [Full Text] [Related]
8. [Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)].
Illés A; Bányai A; Szegedi G
Orv Hetil; 1994 May; 135(22):1187-90. PubMed ID: 8015814
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
10. Greater curability in advanced Hodgkin's disease?
Portlock CS
Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
[No Abstract] [Full Text] [Related]
11. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
Bonadonna G
Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
[TBL] [Abstract][Full Text] [Related]
12. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
13. [Post-MOPP chemotherapy of Hodgkin's disease (author's transl)].
Osieka R; Bruntsch U; Gallmeier WM; Seeber S; Schmidt CG
Dtsch Med Wochenschr; 1976 Aug; 101(32):1177-82. PubMed ID: 59661
[TBL] [Abstract][Full Text] [Related]
14. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
15. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide, and prednimustine.
Cervantes F; Reverter JC; Montserrat E; Rozman C
Cancer Treat Rep; 1986 May; 70(5):665-7. PubMed ID: 3708614
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
18. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
19. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
20. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
Diehl V
J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
[No Abstract] [Full Text] [Related]
[Next] [New Search]
